Nuvalent, Inc. (NUVL) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $123.41: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 11%; Below-average business quality.
Nuvalent is a clinical-stage biopharma developing kinase inhibitors for NSCLC. Zidesamtinib (ROS1-selective) has an NDA accepted by FDA with September 18, 2026 PDUFA date for TKI pre-treated patients; neladalkib (ALK-selective) NDA submission is planned H1 2026, and the Phase 3... Read more
Sell if holding. Engine safety override at $123.41: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 11%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Score 4.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Nuvalent, Inc.
About Nuvalent, Inc.
Nuvalent's lead oncology pipeline spans two clinical-stage programs for NSCLC. Zidesamtinib (NVL-520), a ROS1-selective inhibitor, received FDA NDA acceptance in November 2025 with a PDUFA target action date of September 18, 2026; neladalkib (NVL-655), an ALK-selective inhibitor, had its pre-NDA meeting completed and the company plans to submit an NDA in the first half of 2026. The company reported a net loss of $425.4 million in fiscal year 2025, with an accumulated deficit of $972.4 million.
Nuvalent generates no product revenue; operations are funded entirely through equity financings. Zidesamtinib targets patients with ROS1-positive NSCLC who have received at least one prior ROS1 TKI — the pivotal ARROS-1 dataset covered 117 TKI-pre-treated patients, showing brain-penetrant activity and durable responses. Neladalkib addresses ALK-positive NSCLC across all prior-treatment lines, with the ALKOVE-1 Phase 2 reporting a 31% ORR in 253 TKI-pre-treated patients and 46% in the lorlatinib-naïve subset; the ALKAZAR Phase 3 trial, randomizing patients 1:1 versus alectinib, was initiated in July 2025 with an enrollment target of approximately 450 patients. A third candidate, NVL-330, a HER2-selective inhibitor, entered Phase 1 evaluation via the HEROEX-1 trial in July 2024. Manufacturing depends entirely on third-party contract manufacturers and clinical research organizations.
Show full overview
The entire near-term value rests on the FDA's action on the zidesamtinib NDA by September 18, 2026. There is no approved product and no commercial revenue to absorb a Complete Response Letter or labeling dispute, and the 10-K acknowledges the company cannot assure FDA approval by the PDUFA date, or ever. Existing cash and marketable securities are projected to fund operations into 2029, but if approval is delayed or denied, Nuvalent may need additional capital before that timeline.
See also: Healthcare · Biotechnology
From Nuvalent, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Nuvalent, Inc.
Latest news
- NEWS Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields — benzinga Jun 12, 2026 neutral
- NEWS TD Cowen Downgrades Nuvalent to Hold, Announces $124 Price Target — benzinga Jun 10, 2026 negative
- NEWS This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday — benzinga Jun 10, 2026 neutral
- NEWS Barclays Downgrades Nuvalent to Equal-Weight, Lowers Price Target to $124 — benzinga Jun 10, 2026 negative
- NEWS Wedbush Downgrades Nuvalent to Neutral, Lowers Price Target to $124 — benzinga Jun 10, 2026 negative
Generated 2026-06-17T08:41:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezidesamtinib, neladalkib, and NVL-33010-K Item 1A: 'Our future prospects are substantially dependent on zidesamtinib, neladalkib and NVL-330'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $123.41: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 11%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Prior stop was $114.76. Score 4.2/10, moderate confidence.
Take-profit target: $121.15 (-1.8% upside). Prior stop was $114.76. Stop-loss: $114.76.
Concentration risk — Pipeline: zidesamtinib, neladalkib, and NVL-330; Target reached (-6.6% upside); Quality below floor (1.2 < 4.0).
Nuvalent, Inc. trades at a P/E of N/A (forward -29.8). TrendMatrix value score: 4.0/10. Verdict: Sell.
24 analysts cover NUVL with a consensus score of 4.3/5. Average price target: $128.
What does Nuvalent, Inc. do?Nuvalent is a clinical-stage biopharma developing kinase inhibitors for NSCLC. Zidesamtinib (ROS1-selective) has an NDA...
Nuvalent is a clinical-stage biopharma developing kinase inhibitors for NSCLC. Zidesamtinib (ROS1-selective) has an NDA accepted by FDA with September 18, 2026 PDUFA date for TKI pre-treated patients; neladalkib (ALK-selective) NDA submission is planned H1 2026, and the Phase 3 ALKAZAR trial (vs. alectinib) was initiated July 2025. Both programs are wholly owned with worldwide commercialization rights.